26.08.2016 • News

Recipharm Lifts Italian Lyophilization Capacity

Sweden-based drug developer and toll manufacturer Recipharm is investing €3.7 million in expanding its lyophilization capacity at Masate, Italy, near Milan. The company said the expansion, which is in response to growing customer demand, forms part of its strategy to become a leading lyophilization provider and at the same time complements its €32 million investment in a capacity increase at Wasserburg, Germany.

Recipharm’s Masate, facility specializes in aseptic manufacturing and filling of parenteral and offers lyophilization capabilities in both vials and ampoules. Part of the expansion will be the introduction of a new lyophilizer for vials, increasing output capability by about 20%.

The new lyophilization machinery will allow the toll manufacturer to support more drug developers with their stability challenges and help meet growing demand for lyophilization services from both small and large drugmakers, particularly in Europe, China and Japan, general manager Giorgio Bruno said.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.